Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Operating Expenses: 2009-2024

Historic Operating Expenses for Corcept Therapeutics (CORT) over the last 12 years, with Dec 2024 value amounting to $538.1 million.

  • Corcept Therapeutics' Operating Expenses rose 45.22% to $197.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $675.6 million, marking a year-over-year increase of 39.24%. This contributed to the annual value of $538.1 million for FY2024, which is 43.45% up from last year.
  • Per Corcept Therapeutics' latest filing, its Operating Expenses stood at $538.1 million for FY2024, which was up 43.45% from $375.1 million recorded in FY2023.
  • In the past 5 years, Corcept Therapeutics' Operating Expenses ranged from a high of $538.1 million in FY2024 and a low of $225.7 million during FY2020.
  • Moreover, its 3-year median value for Operating Expenses was $375.1 million (2023), whereas its average is $400.8 million.
  • Data for Corcept Therapeutics' Operating Expenses shows a peak YoY surged of 43.45% (in 2024) over the last 5 years.
  • Corcept Therapeutics' Operating Expenses (Yearly) stood at $225.7 million in 2020, then increased by 7.01% to $241.5 million in 2021, then grew by 19.76% to $289.2 million in 2022, then grew by 29.69% to $375.1 million in 2023, then spiked by 43.45% to $538.1 million in 2024.